Critical MASLD Insights: Predicting Hepatitis B Outcomes
A population-based cohort study of 3,269 adults with chronic hepatitis B in northern China found that coexisting metabolic dysfunction–associated steatotic liver disease (MASLD) was linked to markedly higher long-term risks of cardiovascular disease and extrahepatic cancers over a median follow-up of 13.7 years. After adjusting for lifestyle, metabolic, inflammatory and liver-related factors, MASLD was associated with a 98% higher risk of cardiovascular events and a 50% higher risk of cancers arising outside the liver. Reported cardiovascular outcomes included myocardial infarction and both ischemic and hemorrhagic strokes; the study also reported a 12-year cumulative incidence of cardiovascular disease of 9.4% in people with MASLD versus 4.9% in those without.
At the study baseline, 26.5% of participants had MASLD. Those individuals were more likely to be overweight and to have hypertension, prediabetes or type 2 diabetes than participants without MASLD. The increased risks persisted after multivariable adjustment, indicating that MASLD signals systemic risk beyond traditional liver measures.
Notably, excess cardiovascular risk was present even among participants with only mild liver fat accumulation or with normal alanine aminotransferase (ALT) — a common blood test for liver injury. This suggests that normal liver enzyme results or apparently limited steatosis on imaging may not reliably identify people at lower systemic risk. Cardiovascular risk also remained elevated among participants whose MASLD had resolved by follow-up: those with reversed MASLD showed roughly double the risk of cardiovascular disease compared with individuals who remained free of MASLD, and participants with persistent MASLD faced a similar elevation in risk.
On cancer outcomes, researchers recorded 36 extrahepatic cancers among participants with MASLD and 69 among those without. Persistent MASLD was associated with a 98% higher risk of extrahepatic cancers compared with persistent non‑MASLD. By contrast, MASLD itself was not independently linked to primary liver cancer after adjustment for lifestyle and metabolic variables; instead, the authors found a synergistic interaction between chronic hepatitis B infection and cardiometabolic risk factors that appears to drive primary liver cancer development.
The authors recommend ongoing metabolic management and cardiovascular monitoring for people with chronic hepatitis B, including those with normal ALT levels or resolved hepatic steatosis, and emphasize that both virological control and metabolic health should be incorporated into long-term clinical assessment. Study limitations include lack of longitudinal hepatitis B virus DNA measurements, missing data on antiviral treatment and early fibrosis, and assessment of hepatic steatosis by ultrasonography; the authors note the need to validate findings in populations with different ethnic and lifestyle backgrounds. (Wang X et al., Concurrent MASLD and Long-term Outcomes in HBV-infected Individuals: a population-based cohort study. Biomed Environ Sci. 2026;39(7):785–798.)
Original Source: https://www.emjreviews.com/microbiology-infectious-diseases/news/masld-in-chronic-hepatitis-b-raises-systemic-risks/
Category:
Tags:
Publish Date: 2026-08-07 03:29:00